Results 131 to 140 of about 3,242,366 (329)

Cardiovascular-Kidney-Metabolic Syndrome Among Healthcare Workers in Chinese Tertiary Hospital [PDF]

open access: yes
Qingqing Zhang,1,2,* Jing Zheng,1,* Guoyu Wang,1,3 Suyun Jiang,1 Peng Gao,1 Si Sun,1 Xiangwei Ding,3 Yucheng Wu3 1Department of Pan-Vascular Management Center, The Affiliated Taizhou People’s Hospital of Nanjing Medical University, Taizhou School
Zheng J   +7 more
core  

Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study [PDF]

open access: yes, 2012
AIMS/HYPOTHESIS: Vasopressin plays a role in osmoregulation, glucose homeostasis and inflammation. Therefore, plasma copeptin, the stable C-terminal portion of the precursor of vasopressin, has strong potential as a biomarker for the cardiometabolic ...
Gansevoort, R.T.   +20 more
core   +2 more sources

Role of Sodium-Glucose Transport Protein-2 Inhibitors in Renal Protection: A Narrative Review from the Cardiovascular-Kidney-Metabolic Interconnection

open access: yesDrug Design, Development and Therapy
Nan Ye, Hong Cheng Department of Nephrology, Beijing Anzhen Hospital, Capital Medical University, Beijing, People’s Republic of ChinaCorrespondence: Hong Cheng, Department of Nephrology, Beijing Anzhen Hospital, Capital Medical University, No.
Ye N, Cheng H
doaj  

Impact of DNA‐Methylation Age Acceleration on Long‐Term Mortality Among US Adults With Cardiovascular‐Kidney‐Metabolic Syndrome

open access: yesJournal of the American Heart Association : Cardiovascular and Cerebrovascular Disease
Background The association between DNA methylation age acceleration (DNAmAA) and cardiovascular‐kidney‐metabolic (CKM) syndrome stages and long‐term mortality in the population with CKM syndrome remains unclear.
Shuang Wu   +9 more
semanticscholar   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić   +7 more
wiley   +1 more source

Does diagnosis of the metabolic syndrome detect further men at risk of cardiovascular death beyond those identified by a conventional cardiovascular risk score?

open access: yes, 2007
It is not known whether the metabolic syndrome detects further individuals at high risk of death from cardiovascular disease (CVD), beyond those identified by a conventional cardiovascular risk score.A prospective study.A total of 2790 men without ...
Stehouwer, C.D.A.   +2 more
core   +1 more source

Gene-Gene Interaction between APOA5 and USF1: Two Candidate Genes for the Metabolic Syndrome [PDF]

open access: yes, 2009
Objective: The metabolic syndrome, a major cluster of risk factors for cardiovascular diseases, shows increasing prevalence worldwide. Several studies have established associations of both apolipoprotein A5 (APOA5) gene variants and upstream stimulatory ...
Wichmann, Heinz-Erich   +23 more
core   +1 more source

Current understanding of sodium-glucose transporter 2 inhibitors in cardiovascular-kidney-metabolic syndrome

open access: yesFrontiers in Pharmacology
Cardiovascular-kidney-metabolic (CKM) syndrome is a recently defined clinical entity that encompasses cardiovascular disease (CVD), chronic kidney disease (CKD) and metabolic disorders.
Yan Yang   +4 more
doaj   +1 more source

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay   +5 more
wiley   +1 more source

The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Balcinrenone (previously AZD9977) is a novel selective non‐steroidal mineralocorticoid receptor antagonist (MRA) with a differential mechanism of action relative to approved MRAs. The aim of this trial was to assess the pharmacokinetics, safety and tolerability of balcinrenone in participants with mild and moderate hepatic impairment ...
Anna L. Eriksson   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy